Case Report of Suspected Rhabdomyolysis during Treatment with Trabectedin in a Patient with Metastatic Leiomyosarcoma by Lamm, W. et al.
 
Case Rep Oncol 2010;3:477–479 
DOI: 10.1159/000323261 
Published online: 
December 15, 2010
© 2010 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
This is an Open Access article licensed under the terms of the Creative Commons Attribution-
NonCommercial-NoDerivs 3.0 License (www.karger.com/OA-license), applicable to the online 
version of the article only. Distribution for non-commercial purposes only. 
 
Thomas Brodowicz, MD    Clinical Division of Oncology, Department of Medicine I 
Medical University of Vienna, Waehringer Guertel 18–20 
AT–1090 Vienna (Austria) 
Tel. +43 1 40400 4429, Fax +43 1 40400 4451 
E-Mail thomas.brodowicz @ meduniwien.ac.at 
 
477
   
Case Report of Suspected 
Rhabdomyolysis during 
Treatment with Trabectedin in a 
Patient with Metastatic 
Leiomyosarcoma 
W. Lamma    G. Amannb    T. Brodowicza  
aClinical Division of Oncology, Department of Medicine I, and bDepartment of 
Pathology, Medical University of Vienna, Vienna, Austria 
 
Key Words 
Leiomyosarcoma · Trabectedin · Rhabdomyolysis 
 
Abstract 
Trabectedin has been reported to occasionally induce rhabdomyolysis. In the present 
case, continuation of trabectedin was maintained despite suspected rhabdomyolysis 
related to trabectedin. Creatinine kinase levels dropped to normal levels. We suggest 
that continuation of trabectedin despite suspected rhabdomyolysis was safe in this 
specific patient. 
 
Introduction 
Leiomyosarcomas are rare malignant tumors. Trabectedin is an antineoplastic 
compound isolated from the Caribbean tunicate Ecteinascidia turbinate. It induces tumor 
regression and inhibits tumor growth. This agent is approved as second-line therapy after 
failure of available standard-of-care therapies in leiomyosarcomas. The most common 
grade 3/4 side effects are anemia, thrombocytopenia and transient elevation of liver 
enzymes. 
Case Report 
We describe a case of a 37-year-old male who was admitted to the Vienna General Hospital, Medical 
University Vienna, due to abdominal pain. Magnetic resonance imaging showed a right-sided 
retroperitoneal tumor, infiltrating the right kidney, the right adrenal gland and the inferior caval vein. 
Additionally, an abdominal computed tomography (CT) was performed, which showed further 
metastases in the lymph nodes and ascites. In February 2008, the patient underwent debulking surgery  
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of the tumor, resection of the right kidney and of the inferior caval vein with gore-tex replacement. 
Histopathology revealed a marginally resected leiomyosarcoma G3 of 20 × 11 × 16.5 cm in size. 
Immunohistochemical analysis showed tumor cells positive for vimentin, smooth muscle actin (1A4) 
and, to a lesser extent, for desmin. Reactions with antibodies against CD117 (c-kit), CD34 and p53 were 
negative. A chest CT scan showed multiple metastases also in the lung. The patient rejected initial 
conventional chemotherapy and asked for experimental therapy. Within this context, sorafenib 
treatment [1] was suggested to the patient and subsequently started. Best overall response was stable 
disease, which lasted for 6 months. Subsequent to progression, second-line therapy with doxorubicin 75 
mg/m
2 every 3 weeks was administered. Due to progressive disease after 2 cycles, ifosfamide (1,500 
mg/m
2, day 1–5, every 21 days) was given as third-line therapy with subsequent progression of disease 
after 3 cycles. Thereafter, trabectedin (1.5 mg/m
2 continous infusion over 24 h every 3 weeks) was 
started. Dexamethasone 20 mg and 5HT3 antagonists were administered 30 min before trabectedin 
application. Best overall response was stable disease (SD), which lasted for 11 cycles. In the 8th cycle of 
trabectedin, creatinine kinase (CK) level was elevated to 1,119 U/l (normal range <319 U/l), which was 
confirmed by repetitive measures. Levels of TnT, CK-MB, LDH were within normal values and the 
electrocardiogram showed no abnormalities. Thus, a cardiac causality of the CK elevation was ruled out. 
The patient complained of general muscle pain, but he did not report any previous excessive muscle 
training or trauma. A biopsy of the muscle cell, in order to verify suspected rhabdomyolysis, was refused 
by the patient. Due to the limited availability of further therapeutic options and after careful 
consideration of risks related to continuation of trabectedin and the potential benefit of SD after 8 cycles 
of trabectedin, trabectedin was continued under the condition of extensive monitoring of the patient. 
Three additional cycles of trabectedin were applied. All 3 cycles were dose reduced (1.2 mg/m
2) due to 
elevated serum creatinine levels of 2.12 mg/dl (normal value <1.2 mg/dl). CK levels, which were still 
elevated (≥1.5 × ULN) after the 9th and 10th cycle dropped to 78 U/l, which is normal after the 11th 
cycle. The most recent creatinine level was 2.05 mg/dl, and the patient is doing well. He still has an 
ECOG PS of 0, and a recent CT scan showed SD. 
Discussion 
Leiomyosarcomas are rare malignant tumors of smooth muscle differentiations that 
may arise in any organ or tissue that contains smooth muscle. They comprise less than  
2–9% of sarcomas. Leiomyosarcomas are most frequently found in the stomach and small 
intestine and may also be commonly found in the abdomen and retroperitoneum. 
However, besides the walls of the gastrointestinal tract, they normally arise in the walls of 
large vessels [2]. 
Trabectedin is a marine-derived antineoplastic compound isolated from the Caribbean 
tunicate Ecteinascidia turbinate and currently produced synthetically [3]. This agent 
induces tumor regression and inhibits tumor growth [4]. The efficacy of trabectedin at a 
dose of 1.5 mg/m
2, given intravenously over 24 h every 3 weeks in patients with advanced 
soft tissue sarcomas was previously evaluated in 4 phase II studies [5–8]. In a study by the 
French study group, the most common grade 3/4 toxicities were anemia, 
thrombocytopenia, and transient elevation of liver enzymes (AST/ALT) [9]. 
To the best of our knowledge, this is the first reported case of a continuation of 
trabectedin despite a severe trabectedin-related CK elevation. In this specific case, this 
specific toxicity was reversible and not repetitive under treatment with trabectedin. 
However, reported findings should not be interpreted as suggestion to continue treatment 
regardless of drug-related toxicity. They should rather serve as a description of specific 
findings related to a relatively new drug.  
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